This session will explore novel preparation strategies and applications of Natural Killer (NK) cells, from the generation of NK cells to innovative therapeutic uses NK cell products. Innovative methods and applications of ex vivo expanded NK cells and cord blood NK cells engineered with a CAR will be discussed.
Discuss biopreservation concerns and optimization, and translation into immune cell therapy/regenerative medicine manufacturing and clinical application.
Discuss use of human cord blood to produce NK cells engineered with a CAR to redirect specificity and enhance persistence.
Describe approaches to isolation and ex vivo expansion of NK cells.
Please note: Katy Rezvani, MD, PhD did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.
National Cord Blood Program: DSMB I Erytech: DSMB I B-MoGen Biotech: Scientific Advisory Board I BEST Collaborative: Team Co-Leader/Exec Comm I Icahn School of Medicine: Consultant I CIBMTR/BMT CTN: Medical Monitor I NIH/NEI: DSMB I Gamida: Clinical trial product manufacturing I Fate Therapeutics: Clinical trial product manufacturing I Intima: Clinical trial product manufacturing I Magenta: Clinical trial product manufacturing I NMDP: Donor and Patient Safety Monitoring Advisory Group I NIH/NHLBI: Research funding
Katy Rezvani, MD, PhD :
Affimed, Pharmacyclics: Grant/Research Support (Secondary Investigators need not disclose) I EMD Serono; Adicet Bio; Onkimmune; Formula Pharma; Virogen: Consultant I SAB: Formula Pharma; Virogen, Kiadis Pharma: Membership on advisory committees or review panels, board membership, etc.
Thomas Spitzer, MD :
ITB-Med: Scientific Advisory Board I Jazz Pharmaceuticals: Adjudication Board I BluebirdBio: Data Monitoring Committee I Janssen Pharmaceuticals: Honoraria I Vedanta Biosciences: Consultant